China’s Pharmaceutical Enterprise R&D Index 2022 Released: Two Enterprises of Lianyungang Ranking in the Top 10

From: Lianyungang Daily Updated: 2023-09-10 09:19

The research and development index of Chinese pharmaceutical enterprises in 2022 was officially released at the "Health and Pharmaceutical Industry Innovation Service Conference 2023" of China International Fair for Trade in Service. Hengrui Pharmaceuticals Co., Ltd. and Hansoh Pharmaceutical Group Co., Ltd. ranked in the top ten of the research and development index of non device Chinese pharmaceutical enterprises with a final index of 73.64 and 63.41 respectively, with Hengrui Pharmaceuticals ranking first and Hansoh Pharmaceutical Group ranking ninth. Zhou Mengling, Deputy Director of the Municipal Science and Technology Bureau, introduced that the main driving factor for the rise in the R&D index of non device Chinese pharmaceutical enterprises is the improvement of R&D quality. In recent years, with the high-quality development of the pharmaceutical industry in our city, the research and development quality of pharmaceutical enterprises has significantly improved, and the efficiency of new drug research and development has continued to accelerate.

It is learned that China’s Pharmaceutical Enterprise R&D Index 2022 focuses on listed pharmaceutical companies in China and is jointly released by National Small & Medium Enterprises Council, National Health Commission's Medical and Health Technology Development Center, Chinese Society of Pharmaceutical Accounting, the Digital Finance and Taxation Research Institute of Beijing Jiaotong University, and National Pharmaceutical Industry Information Center. At the conference, the "White Paper 2022 on the R&D Index of Chinese Pharmaceutical Enterprises" was released at the same time. China’s Pharmaceutical Enterprise R&D Index aims to construct a comprehensive and scientific evaluation index system for pharmaceutical enterprise R&D that covers R&D investment and achievements, as well as R&D quality and support, in order to systematically, comprehensively and scientifically evaluate the R&D level and capabilities of Chinese pharmaceutical enterprises.

As a pillar industry that has grown locally, Lianyungang's pharmaceutical industry attaches great importance to research and development innovation, and many pharmaceutical enterprises have a research and development proportion that ranks among the top in the country. Among them, Hengrui Pharmaceuticals has invested 29.2 billion yuan in research and development in the past decade, ranking among the top in the national pharmaceutical industry. Up till now, pharmaceutical companies in our city have established dozens of research and development centers both domestically and internationally, with nearly 10000 global research and development teams. At the same time, extensive layout has been carried out in fields such as tumors, autoimmune diseases, metabolic diseases, cardiovascular diseases, infectious diseases, respiratory system diseases, blood diseases, pain management, nervous system diseases, ophthalmology, nuclear medicine, gynecology, liver diseases and etc.

Thanks to deep cultivation in multiple fields, rich R&D pipelines, and continuous R&D layout, our city's pharmaceutical industry R&D transformation achievements are accelerating their implementation. Nowadays, more than 20 self-developed innovative drugs and introduced innovative drugs have been approved for market launch, and more than 200 self-developed innovative products are currently under clinical development. Nearly 400 clinical trials have been conducted both domestically and internationally, with research and development achievements firmly occupying a leading position in the industry. In addition, a group of international first-class new technology platforms with independent intellectual property rights have been established, including protein hydrolysis targeted chimeras (PROTAC), molecular gels, antibody conjugated drugs (ADC), dual/multi specific antibodies, AI molecular design, drug resistance, in vivo pharmacology, molecular dynamics, bioinformatics, as well as a number of smart factories and workshops.

Data shows that as of June this year, Hengrui has applied for 2208 invention patents, 572 domestic patent authorizations, 622 PCT patent applications and 656 foreign authorizations, including those in Europe, America and Japan. Hengrui has successively won one gold award of Chinese invention patent, two silver awards of Chinese invention patent and two excellence awards of Chinese invention patent; Hengrui undertook 57 national major special projects, won 2 second prizes for core technology and 10 other scientific and technological progress awards. Hansoh Pharmaceutical Group has established a research and development system covering the whole process from cutting-edge information collection, compound design and screening, pharmacological and toxicological research to clinical medical research, and has created a number of national research and development institutions such as the National Enterprise Technology Center, postdoctoral research workstation and State Key Laboratory; Hansoh Pharmaceutical Group undertook 60 national level scientific research projects such as the 863 Plan, the special key technological project "Major New Drug Creation" and the Torch Plan. They obtained 499 domestic and foreign authorized invention patents and received 2 National Science and Technology Progress Awards and 2 National Patent Gold Awards.